Laboratory Testing for Potential Liver Disease

Initial Investigation

• The British Society of Gastroenterology recommends initial investigation for potential liver disease should include bilirubin, albumin, ALT, ALP, and GGT, together with a full blood count if not already performed within the previous 12 months 1
• Bilirubin assesses hepatic excretory function and cholestasis 1
• Albumin reflects hepatic synthetic function and chronicity of disease 1
• Alanine aminotransferase (ALT) is a primary marker of hepatocellular injury 1
• Alkaline phosphatase (ALP) indicates cholestatic or infiltrative disease 1
• Gamma-glutamyl transferase (GGT) increases sensitivity for detecting alcohol-related and fatty liver disease, and is associated with increased liver and all-cause mortality 1
• Full blood count, including platelet count, helps assess for portal hypertension and advanced fibrosis 1

Etiologic Testing

• Hepatitis B surface antigen (HBsAg) and hepatitis B core IgM should be tested for viral hepatitis serologies 2
• Hepatitis C antibody (HCV Ab) should be tested for viral hepatitis serologies 2
• For marked elevations (ALT >1000 U/L), add hepatitis A, hepatitis E, and cytomegalovirus serologies 2
• Serum immunoglobulin G (IgG) is elevated in autoimmune hepatitis 2
• Antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-liver kidney microsome (LKM) antibodies should be tested for autoimmune markers 1, 2
• Antimitochondrial antibody (AMA) should be tested for primary biliary cholangitis 1

Metabolic Parameters

• Fasting glucose or hemoglobin A1c should be assessed for NAFLD evaluation 2
• Lipid panel (triglycerides, cholesterol) should be assessed for NAFLD evaluation 2
• Assessment for metabolic syndrome components (waist circumference, BMI, blood pressure) should be performed 3, 4

Non-Invasive Fibrosis Assessment

• FIB-4 score values <1.3 indicate low risk of advanced fibrosis (<2.0 for age >65 years) 5, 6
• NAFLD Fibrosis Score values ≤-1.455 indicate low risk (≤-0.12 for age >65 years) 5
• Enhanced Liver Fibrosis (ELF) test is a serum biomarker panel for second-line fibrosis testing 5
• Transient elastography (FibroScan) values >7.8 kPa suggest advanced fibrosis 5

Imaging Recommendations

• Abdominal ultrasound with Doppler is the initial imaging modality of choice, with 84.8% sensitivity and 93.6% specificity for moderate to severe hepatic steatosis 2
• CT abdomen/pelvis with IV contrast may be considered for moderate to severe elevations or when ultrasound is inadequate 2

Referral Criteria

• Unexplained clinical jaundice requires immediate specialist referral 2
• Suspicion of hepatic or biliary malignancy requires immediate specialist referral 2
• Evidence of hepatitis B, HCV, autoimmune hepatitis, or hemochromatosis requires immediate specialist referral 2
• Findings concerning for cirrhosis, such as thrombocytopenia, AST>ALT, hypoalbuminemia, elevated INR, require immediate specialist referral 4

Guideline‑Recommended Laboratory Evaluation for Hepatomegaly

Assessment of Hepatic Synthetic Function

• Prothrombin time/INR is used to evaluate hepatic synthetic capacity and coagulation status according to the National Comprehensive Cancer Network (NCCN) guidelines. 7
• Platelet count serves as a surrogate marker for portal hypertension and advanced fibrosis in the NCCN recommendations. 7

Virologic Testing for Infectious Etiologies

• Screening for hepatitis B infection should include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb, both IgG and IgM) as advised by NCCN. 7
• Positive serology for HBsAg, HBcAb IgG, or hepatitis C antibody (HCV Ab) requires quantitative viral load confirmation per NCCN guidance. 7

Autoimmune and Metabolic/Infiltrative Screening

• Antimitochondrial antibody (AMA) testing is recommended for suspected primary biliary cholangitis when a cholestatic laboratory pattern is present, per Hepatology Society guidelines (2009). 8
• Comprehensive iron studies (serum iron, TIBC, ferritin, transferrin saturation) are advised to screen for hereditary hemochromatosis according to Hepatology guidelines (2011). 9
• Alpha‑fetoprotein (AFP) measurement is indicated when hepatocellular carcinoma is suspected, but clinicians should recognize its limited specificity, as highlighted by NCCN (2021). 10

Evaluation of Hepatic Functional Reserve

• Blood urea nitrogen and serum creatinine are obtained to assess renal function; serum creatinine is an established prognostic marker in chronic liver disease per NCCN recommendations. 10
• The Child‑Pugh score—incorporating albumin, bilirubin, PT/INR, encephalopathy, and ascites—is calculated to stage cirrhosis severity in NCCN guidelines. 7
• The Model for End‑Stage Liver Disease (MELD) score, using bilirubin, creatinine, and INR, is employed to prioritize patients for liver transplantation per NCCN. 7

Non‑Invasive Fibrosis Assessment

• The AST‑to‑Platelet Ratio Index (APRI) can identify advanced fibrosis and portal hypertension, as supported by Hepatology Society evidence (2024). 11
• The GGT‑to‑Platelet Ratio (GPR) is useful for detecting early biliary disease, according to recent Hepatology data (2024). 11

Interpretation Caveats

• Ferritin levels may be falsely elevated in inflammatory states, necroinflammatory liver disease, lymphomas, and other chronic inflammatory conditions; interpretation should consider these confounders per Hepatology guidelines (2011). 9
• AFP lacks disease‑specificity and can be elevated in pregnancy, chronic HBV/HCV infection, intra‑hepatic cholangiocarcinoma, and other malignancies, as noted by NCCN (2021). 10

Initial Investigations for Suspected Viral Hepatitis (NCCN Guidelines)

Comprehensive Serologic Testing

• Order a hepatitis panel that includes HBsAg, hepatitis B surface antibody, hepatitis B core antibody (IgG and IgM), and HCV antibody, together with liver function tests (ALT, AST, bilirubin, alkaline phosphatase, albumin, PT/INR) and a complete blood count with platelets. 12
• Include HBsAg to detect active hepatitis B infection. 12
• Include HBV surface antibody to assess immunity against hepatitis B. 12
• Include HBcAb IgG because isolated IgG may still indicate chronic hepatitis B infection. 12
• Include HBcAb IgM when evaluating patients who present with acute viral hepatitis. 12
• Include HCV antibody for hepatitis C screening. 12

Confirmation of Active Replication

• If HBsAg, HBcAb IgG, or HCV antibody test positive, obtain quantitative viral‑load testing (HBV DNA or HCV RNA) to confirm active replication and determine need for hepatology referral. 12

Liver Function Assessment

• Measure ALT and AST as primary markers of hepatocellular injury. 12
• Measure bilirubin to evaluate hepatic excretory function. 12
• Measure albumin to reflect synthetic function and disease chronicity. 12
• Measure PT/INR to assess coagulation and synthetic capacity. 12
• Measure platelet count as a surrogate marker for portal hypertension. 12

Renal Function and Prognostic Markers

• Obtain blood urea nitrogen and creatinine to assess renal function; serum creatinine serves as an established prognostic marker in liver disease. 12

Tumor Marker Utility

• Alpha‑fetoprotein (AFP) has limited utility in acute hepatitis; imaging studies provide more definitive evaluation for hepatocellular carcinoma suspicion. 12

Laboratory Assessment and Non‑Invasive Staging in Chronic Liver Disease

Initial Core Laboratory Panel

• All adults with suspected or known chronic liver disease should have a standardized baseline panel that includes bilirubin (total and direct), albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ‑glutamyl transferase (GGT), and a complete blood count if not performed within the previous 12 months 13.
• This core panel supplies essential information on hepatocellular injury, cholestasis, synthetic function, and the risk of portal hypertension 14.
• ALT and aspartate aminotransferase (AST) are the primary laboratory markers of hepatocellular injury 14.
• ALP and GGT are the primary laboratory markers of cholestasis and biliary obstruction 14.
• Serum albumin reflects hepatic synthetic capacity and chronicity of disease 13.
• Total and direct bilirubin assess hepatic excretory function 13.
• Prothrombin time/International Normalized Ratio (INR) evaluates coagulation and synthetic function 15.
• Platelet count serves as a surrogate marker for advanced fibrosis and portal hypertension 16.

Etiologic Screening (Core Panel)

• Once abnormal liver tests are identified, a comprehensive etiologic work‑up must be performed regardless of the degree or duration of abnormality 14.
• Viral hepatitis serologies – Hepatitis B surface antigen (HBsAg) to detect active HBV infection 14; hepatitis C antibody with reflex PCR to confirm active HCV infection 14; for marked ALT elevations (> 1000 U/L) add hepatitis A IgM, hepatitis E IgM, and cytomegalovirus serologies 14.
• Autoimmune markers – Anti‑mitochondrial antibody (AMA) for primary biliary cholangitis 14; anti‑smooth muscle antibody (ASMA) for autoimmune hepatitis 14; antinuclear antibody (ANA) for autoimmune conditions 14; elevated serum IgG suggests autoimmune hepatitis 14.
• Metabolic screening – Simultaneous serum ferritin and transferrin saturation; a saturation > 45 % is considered significant for hereditary hemochromatosis 14.
• Imaging – Abdominal ultrasound is mandatory in the initial work‑up to evaluate liver architecture, detect steatosis, identify focal lesions, and assess for biliary obstruction 14.

Non‑Invasive Fibrosis Assessment

• Patients with confirmed chronic liver disease require fibrosis staging to identify compensated advanced chronic liver disease (cACLD) [17][18].

First‑Line Fibrosis Scores

• A FIB‑4 score ≥ 1.30 (or ≥ 1.75 for higher specificity) identifies individuals who should proceed to liver stiffness measurement [17][18]13.
• The NAFLD Fibrosis Score (NFS) can be used as an alternative first‑line test 13.

Second‑Line Assessment (Transient Elastography)

• Liver stiffness measurement (LSM) ≥ 10 kPa on transient elastography suggests cACLD; LSM ≥ 15 kPa is highly suggestive of cACLD [17][18].
• LSM 10–15 kPa combined with a platelet count > 150 000/µL helps rule out cACLD [17][18].
• LSM ≥ 8 kPa together with FIB‑4 ≥ 1.30 warrants referral to hepatology [17][18].

Monitoring and Surveillance for cACLD

• Patients with established cACLD should undergo laboratory monitoring every 6–12 months 16.

• In patients who have achieved sustained virologic response (SVR), an LSM < 12 kPa and platelet count > 150 000/µL obviates the need for screening endoscopy for varices 16.

Hepatocellular Carcinoma (HCC) Surveillance

• Individuals with cACLD, prior portal‑hypertension complications, or a history of HCC require ongoing surveillance even after successful etiologic therapy [17][18].
• Abdominal ultrasound every 6 months is recommended for HCC screening [17][18] (AFP measurement may be added but has limited specificity).

Key Pitfalls and Practical Considerations

• Isolated elevated ferritin does not confirm hemochromatosis; it may be raised in dysmetabolic iron overload, alcohol excess, NAFLD, and other chronic liver diseases 14.
• Country of origin (rather than ethnicity) is the strongest predictor of viral hepatitis prevalence; screening strategies should be tailored accordingly 14.
• In patients with metabolic risk factors who have never been exposed to HBV or HCV, a FIB‑4 ≥ 1.30 should be used as the initial diagnostic tool before proceeding to liver stiffness measurement [17][18].

Immediate Hepatology Referral Criteria

• Positive HBsAg or HCV antibody with detectable viral load (viral replication) 14.
• Positive AMA indicating primary biliary cholangitis 14.
• Elevated IgG together with positive autoantibodies (ASMA, ANA) suggestive of autoimmune hepatitis 14.
• Transferrin saturation > 45 % with elevated ferritin indicating probable hereditary hemochromatosis 14.
• Imaging showing dilated bile ducts 14.
• Combined FIB‑4 ≥ 1.30 and LSM ≥ 8 kPa indicating cACLD [17][18].
• Clinical evidence of hepatic decompensation (thrombocytopenia, AST > ALT ratio, hypoalbuminemia, elevated INR) 16.